

**A** MERICAN  
**A** SSOCIATION OF  
**C** HINESE IN  
**T** OXICOLOGY



北美中華毒理協會

# American Association of Chinese in Toxicology (AACT)

## Annual Business Meeting

**April 28, 2022**



# Agenda

- ☞ Welcome & Greetings
- ☞ Business meeting
  - President's report
  - Treasurer's report
  - Results of election (the Past President)
  - AACT award presentations (Secretary)
  - Appreciation for outgoing board members
  - Incoming President's agenda and initiatives
- ☞ Gold sponsors' presentations
- ☞ Open discussion
- ☞ Adjournment

**A** MERICAN  
**A** SSOCIATION OF  
**C** HINESE IN  
**T** OXICOLOGY



北美中華毒理協會

## President's Report

**Nan Mei**


# Why the AACT Business Meeting was not held during the 61<sup>st</sup> Annual Meeting (San Diego, March 27-31, 2022)?

- ❖ The 59<sup>th</sup> Annual Meeting was scheduled on **March 15-19, 2020, in Anaheim, CA**. Due to the COVID-19 pandemic, this meeting was cancelled. The part of sessions was virtually organized from March to June.
- ❖ The 60<sup>th</sup> Annual Meeting was a **virtual meeting** on March 12-26, 2021.
- ❖ The 61<sup>st</sup> Annual Meeting was on **March 27-31, 2022, in San Diego, CA**.
  - Since May of 2021, we had planned to have the AACT Reception during the annual meeting.
  - Due to the highly transmissible Omicron variant in **January**, we conducted a survey.
  - With a small number of responses, AACT Board Members decided to cancel the reception and organize a virtual business meeting.

# AACT Virtual Meeting on March 25, 2021

Recording...

 <p>Nan Mei</p>	 <p>Hao Chen</p>	 <p>SOT   Society of Technology Yongbin Zhang</p>	 <p>Zunwei Chen</p>	 <p>iPad</p>
 <p>Lu Cai</p>	 <p>Weimin Chen</p>	 <p>Christine Wei</p>	 <p>LZhan</p>	 <p>Miaofei Xu</p>
 <p>Tira</p>	 <p>Shengjie Xu</p>	 <p>Jim J Liu</p>	 <p>Charles Wang</p>	 <p>Xiaoqing Guo, U...</p>



Dongying Li

Meng Sun

Wei-Chun Chou



# AACT Business Meeting on March 28, 2022

Event ID: 20

Thank you for sending SOT your ancillary meeting request form. Your meeting has been approved, and we have now assigned your meeting space. We look forward to your participation in the Society of Toxicology's Annual Meeting in San Diego for the week of March 27-31, 2022. Your meeting details are as follows:

Organization: American Association of Chinese in Toxicology (AACT)

Title: American Association of Chinese in Toxicology Special Interest Group Distinguished Chinese Toxicologist Lectureship Award and Reception

Date: Monday, March 28, 5:00 PM-9:00 PM

Listed in Annual Meeting Yes

Materials:

Location: Marriott Marquis San Diego Marina (Headquarters Hotel)  
333 West Harbor Drive, San Diego, CA 92101  
Room: Pacific Ballroom 16, 17, 19

### Recent Surveys

**OPEN**

Please let us know if you plan to attend the AACT reception on March 28, 2022. Please respond by Jan...

Created: 01/18/2022 | Modified: 01/25/2022

<b>38</b> Responses	100% Completion rate	1 min Typical time spent	⋮ Options
------------------------	-------------------------	-----------------------------	--------------

Showing 1 of 1 survey.

**CREATE**

Feedback

Help

### Survey Examples


See what kinds of insights you can discover from survey results. Here is an example of an imaginary company with a realistic challenge. [See all examples.](#)

10:32 AM  
2/1/2022

## 2022 January Survey

# AACT Board Members

## AACT Board Officers



AMERICAN  
ASSOCIATION OF  
CHINESE IN  
TOXICOLOGY



北美中華毒理協會

# AMERICAN ASSOCIATION OF CHINESE IN TOXICOLOGY



北美中華毒理協會

AACT has 228 members (as 05/27/2021), is the 3<sup>rd</sup> largest Special Interest Group



**Nan Mei**  
President



**Xi Yang**  
President-Elect



**Yongbin Zhang**  
Past President



**Xiaoqing Guo**  
Secretary



**Quanshun Zhang**  
Treasurer



**Dongying Li**  
Councilor



**Xiefan Fang**  
Councilor




**Hao Chen**  
Postdoc Rep




**Shengjie Xu**  
Student Rep

# AACT Board Members (2021-2022)

## AACT Board Officers



AMERICAN  
ASSOCIATION OF  
CHINESE IN  
TOXICOLOGY



北美中華毒理協會

# SOT Award Nomination Committee

- ❖ To promote the recognition of accomplished toxicologists of Chinese origin by nominating them for SOT awards
- ❖ Submitted 1 nomination package in 2021 (*3 in 2019 and 1 in 2020*); each nomination package stays active for **three years**
- ❖ **One of the previous AACT nominations won in 2022**


**Dr. Yue Cui**

**Associate Professor**

**Department of Environmental & Occupational Health Sciences**

**University of Washington**

**2022 SOT Achievement Award**



**AACT Board would like to encourage all toxicologists in Chinese origin to be forthright and proactive in recognizing yourself or your colleagues' accomplishment!**

# Building opportunities beyond annual meeting

## – Career Development

- ❖ AACT survey indicates a main reason for toxicologists to join AACT is to enhance career development opportunities
- ❖ Board discussed how to strengthen network opportunities and promote career development for students, postdocs and junior scientists, and how to facilitate a long-term AACT mentor-mentee relationships
- ❖ 2022 summer mentoring and network program – [look out for registration invitations!](#)



- ✓ Currently, having **357** members (vs. 228 AACT-SOT members)
- ✓ Q & A
- ✓ Job information (both in USA and China)
- ✓ Information for students and postdoctoral fellows

**AACT Board would like to encourage students, postdocs, and scientists to utilize these opportunities**

# New AACT Award Information

- Best Abstract Award (est. 2005, currently supported by InnoStar from 2018, three winners)
- Distinguished Chinese Toxicologist Award (est. 2006, currently supported by WestChina-Frontier PharmaTech from 2022, one winner)
- Jean Lu Student Scholarship Award (est. 2009; New, two winners)
- New Award: Outstanding Young Toxicologist Award (est. 2021 and first awarded in 2022; supported by Joinn Biomere from 2021, two winners)



- Suggestion: Best Publication Award ??? (only 2005; 1 or 2, PhD student and/or postdoctoral fellow, any sponsor???)

# Distinguished Chinese Toxicologist Award

**2020 Winner**



**Lu Cai, MD, PhD**  
Professor,  
School of Medicine  
University of Louisville  
Louisville, USA

**2021 Winner**



**Ke Jian Liu, PhD**  
Professor  
College of Pharmacy  
University of New Mexico  
Albuquerque, USA



# Outreach Activities in China

## AACT Session in ASIATOX-IX

# ASIATOX 2021

The 9<sup>th</sup> International Congress of ASIATOX  
The 8<sup>th</sup> CST Youth Forum of Science & Technology  
第九届亚洲毒理学大会  
暨中国毒理学会第八次中青年科技论坛

October 20-23, 2021 Hangzhou · China / Virtual

## 会议指南

Friday, 22 October

SS: COVID-19 Vaccines and Therapeutics: from Industry to Regulatory Perspectives  
Chair: Nan Mei, Yongbin Zhang

Baosheng Hall 1

8:00-8:10 The introduction of SOT and AACT  
Yongbin Zhang

8:10-8:40 Overview of non-clinical safety assessment for antiviral drugs and vaccines development  
Hanan Ghantous (FDA/CDER, USA)

8:40-9:10 Non-clinical safety assessment for preventative vaccines development  
Nabil Al-Humadi (FDA/CBER, USA)

9:10-9:35 Rapid development of REGN-COV2, an anti-spike antibody cocktail for treatment and prevention of COVID-19  
Matt Y. Liu (Regeneron Pharmaceuticals, USA)

9:35-10:10 Development of mRNA COVID-19 vaccine BNT162b2 in China  
Aimin Hui (FosunPharma, China)



### BNT162b2 mRNA vaccine efficacy 100% in Adolescents (12-15yr)


#### Vaccine Efficacy - 100%

Table 3. Vaccine Efficacy against Covid-19 in Participants 12 to 15 Years of Age.<sup>a</sup>

Efficacy End Point <sup>b</sup>	BNT162b2		Placebo		% Vaccine Efficacy (95% CI) <sup>c</sup>
	No. of Participants with Event/Total No. §	Surveillance Time (No. at Risk)¶	No. of Participants with Event/Total No. §	Surveillance Time (No. at Risk)¶	
Covid-19 occurrence at least 7 days after dose 2 in participants without evidence of previous infection	0/1005	0.154 (1001)	16/978	0.147 (972)	100 (75.3-100)
Covid-19 occurrence at least 7 days after dose 2 in participants with or without evidence of previous infection	0/1119	0.170 (1109)	18/1110	0.163 (1094)	100 (78.1-100)



- BNT162b2 had a favorable safety and side-effect profile, with mainly transient mild-to-moderate reactogenicity (predominantly injection-site pain, fatigue and headache).
- there were no vaccinerelated serious adverse events and few overall severe adverse events
- The GMT of SARS-CoV-2 50% neutralizing titers after dose 2 in 12-to-15-year-old participants relative to 16-to-25-year-old participants was 1.76, which met the noninferiority criterion of a lower boundary of the two-sided 95% confidence interval greater than 0.67 and indicated a greater response
- The observed vaccine efficacy was 100% (95% CI, 75.3 to 100).

#### Local Events after 2 dose



Robert W. Frencik et al. N Engl J Med 2021; 385(3): 239-250.

#### Systemic Events after 2 dose






## Treasurer's Report

Quanshun Zhang





## AACT Financial Statement

- 2021–2022 Jean Lu Student Scholarship Award Fund Endowment  
Fund Disbursement: June 30, 2021, the Fund balance is **\$48,608**.  
Available funds for disbursement for 2021–2022 awards are **\$1,944**.
- Received Sponsorship: Total **\$9,500** from Joynn Biomere (\$3,000);  
Innostar (\$3,000); WestChina-Frontier PharmaTech (\$3,000);  
Genentech (\$500).
- Previous Year Fund: **\$74,455**
- Totally fund: **\$83,955**



# Shout-out to Our 2021-2022 Sponsors!

## Gold Sponsors



## Bronze Sponsors





北美中華毒理協會

## Election Report

Yongbin Zhang




# AACT New Officers Elections

## 🌀 Election Committee

- Chair: Yongbin Zhang
- Nan Mei, Xi Yang, Xiaoqing Guo, Shengjie Xu

## 🌀 Open positions

- President-Elect (1)
- Councilors (2)
- Postdoc representative (1)
- Student representative (1)



# Congratulations to newly elected AACT Board Members!

---



**President-Elect**

**Kan Shao, PhD**


Indiana University School of Public Health

# Congratulations to newly elected AACT Board Members!

---




**Councilor**  
**Xiaoling (Sharlene) Dai, PhD**  
Abbott Laboratories



**Councilor**  
**Zhenquan Jia, PhD**  
University of North Carolina


# Congratulations to newly elected AACT Board Members!

---



**Postdoc Representative**

Jie (Daniel) Luo, PhD  
Duke University



**Student Representative**

Yunqi An, MSc  
Rutgers, The State University of New Jersey

**A**merican  
**A**ssociation of  
**C**hinese in  
**T**oxicology



北美中華毒理協會

## Award Presentations

**Xiaoqing Guo**



# WestChina-Frontier PharmaTech Distinguished Chinese Toxicologist Award of AACT

---

In recognition of outstanding achievements as a scientist, and  
leader in toxicology



**Menghang Xia, PhD**

**Group Leader of Systems Toxicology**

Division of Pre-Clinical Innovation,

National Center for Advancing Translational Sciences

(NIH/NCATS)

# US Tox21 Program – *In Vitro* Toxicology

Menghang Xia, Ph.D.

*Division of Pre-Clinical Innovation*

*National Center for Advancing Translational Sciences*

*National Institutes of Health*

# About My Career



## Education



- 1993-1996 ● University of California at San Francisco  
Postdoctoral Fellow
- 1993 ● State University of New York  
PhD, Pharmacology
- 1983 ● Shanghai Medical University  
Bachelor of Medicine, Toxicology Major



## Employment




National Center  
for Advancing  
Translational Sciences


- 2005 - Present ● NCATS/NIH  
Group Leader of Systems Toxicology
- 1998 ● Merck research lab  
Senior Scientist
- 1996 ● Amgen  
Scientist



# Tox21 Program - Toxicology in the 21st Century




In vitro qHTS assays



- Identification of mechanisms of compound action
- Prioritization of chemicals for more extensive toxicological evaluation
- Development of predictive models for biological response in humans


# Tox21 Screening and Cross-partner Projects

➤ **Co-Chair** in Assay Evaluation & Screening team, Cross-partner projects, Tox21 Program



## Publications and Presentations

- > 200 Research manuscripts, book chapters, patents
- 2 books
- > 60 Podium presentations



>100 Online Screens against the Tox21 10K compound collection



Total Assay IDs (AIDs): > **200 AIDs**  
Total public data points > **100 million**

## Training Next Generation of Scientists

- 13 Postdocs, graduate students, and visiting scholars
- 15 Postbacs and summer interns

# Postdoctoral Fellowship Opportunity at NCATS

We are seeking a self-motivated postdoctoral fellow to work on the Tox21 research projects in development of physiologically relevant assays for assessment of environmental chemicals. The NCATS has a unique and exciting environment employing state-of-art technologies on assay development, chemical screening, and profiling for toxicology research.

The fellow will develop in vitro cell-based assays using physiologically relevant cell models (primary cells, stem cell/iPS-derived cells, and 3-D cell/organoid models) with biotransformation-capability for screening chemicals. The fellow will apply new technologies including 3-D cell/organoid models and high content phenotypic profiling using cell-based imaging assays for evaluating chemical toxicity. The fellow will perform follow-up studies (e.g., mechanisms of compound action) after the primary screening. The fellow will also interact regularly with informatics scientists to aid data analysis and interpretation.


Minimum requirements include a Ph.D. degree in life science fields including toxicology, pharmacology, biology, cell biology, and biochemistry, with solid understanding of toxicology, cell biology, or general aspects of signal transduction. Experience in assay development including biotransformation-capable assays, imaging technology, or compound screening is a plus. Basic data analysis skills and familiarity with Excel spreadsheets are desired. Effective oral and written communication skills combined with high level of motivation and ability to thrive in an interactive, fast-paced environment are also preferred.

**Scientific contact: Menghang Xia, [mxia@mail.nih.gov](mailto:mxia@mail.nih.gov)**

Applicants should send a letter stating their research interests and goals, a CV including bibliography, and arrange for three letters of reference to be sent by e-mail to the respective scientific contacts.

# Joinn Biomere Outstanding Young Toxicologist Award of AACT

**NEW**



**Zhoumeng Lin, PhD**  
**Associate Professor**

Department of Environmental and Global Health  
University of Florida

An individual who  
has made  
significant  
contributions to  
the toxicology  
field in the early  
stage of their  
career



**Kan Shao, PhD**  
**Associate Professor**

Department of Environmental and Occupational Health  
Indiana University School of Public Health - Bloomington

# Introduction of the Computational Toxicology and Pharmacometrics Laboratory at the University of Florida

Zhoumeng Lin, BMed, PhD, DABT, CPH

Center for Environmental and Human Toxicology (CEHT) & Center for Pharmacometrics and Systems Pharmacology (CPSP)  
Department of Environmental and Global Health, College of Public Health and Health Professions (primary appointment)  
Department of Physiological Sciences, College of Veterinary Medicine (jointly appointed)  
Department of Pharmaceutics, College of Pharmacy (jointly appointed)  
University of Florida, Gainesville, FL 32610

# Self-introduction – Career Trajectory and Credentials

## 09/2004-06/2009

- Bachelor of Medicine (BMed) in Preventive Medicine

## 08/2009-12/2013

- PhD in Toxicology
- Toxicology, Exposure, Risk Assessment, and Computational Modeling (e.g., PBPK)

## 02/2014-01/2016

- Postdoc in Computational Toxicology and Pharmacometrics
- PBPK models for nanoparticles and drugs
- Mice, rats, humans, swine, cattle, and goats

## 01/2016-05/2021

- Computational Toxicology and Pharmacometrics (e.g., PBPK Modeling)
- 11/2017:** Diplomate of American Board of Toxicology (DABT)
- 03/2019:** Certified Pharmacometrician
- 08/2019:** Certified in Public Health (CPH)
- 03/2021:** Promoted to Associate Professor with tenure

## 05/2021-present





- Associate Professor with tenure
- Computational Toxicology and Pharmacometrics (e.g., PBPK Modeling)



by National Board of Public Health Examiners



# Research Program in Computational Toxicology and Pharmacometrics




We develop computational models to address nanomedicine, animal-derived food safety, human health risk assessment issues!

**Nanomaterials**

**Environmental chemicals**

**Drugs**

# Team




Wei-Chun Chou  
 Research Assistant Professor  
 PhD in Biomedical Engineering and Environmental Science  
 National Tsing-Hua University



Long Yuan  
 Postdoctoral Fellow  
 PhD in Pharmaceutical Science  
 University of Cincinnati



Qiran Chen  
 Postdoctoral Fellow  
 PhD in Environmental Health  
 Indiana University



Zhoumeng Lin



Dachuan Zhang  
 Postdoctoral Fellow  
 PhD in Computational Biology  
 (accepted, beginning in Fall 2022)  
 University of Chinese Academy of Sciences



Pei-Yu Wu  
 PhD Student  
 (accepted, beginning in Fall 2022)  
 MS in Food Safety and Health Risk Assessment  
 National Yang-Ming University



Xue Wu  
 PhD Student  
 (accepted, beginning in Fall 2022)  
 BVSc/DVM  
 Huazhong Agriculture University

# Team – Lab Alumni

## ***Postdoctoral Fellows:***

- Miao Li, 2016.08-2019.08, First Position: Visiting Scientist, National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), Jefferson, AR
- Yi-Hsien Cheng, 2016.12-2020.12, First Position: Pharmacologist/Biopharmaceutical Scientist – Investigator III, US Food and Drug Administration (FDA), Silver Spring, MD
- Wei-Chun Chou, 2018.08-2021.05, First Position: Research Assistant Professor, Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida
- Md Mahbubul Huq Riad, 2020.09-2021.10, First Position: Senior Quantitative Systems Pharmacologist I, AbbVie, North Chicago, IL

## ***Undergraduate Students:***

- Trevor Elwell-Cuddy, 2016.08-2018.05, First Position: PBPK modeler in the Wright–Patterson Air Force Base
- Sichao Mao, 2018.01-2018.06, First Position: DVM student at Iowa State University
- Yilei Zheng, 2018.01-2018.06, First Position: DVM student at University of Minnesota
- Yu-Shin Wang, 2018.06-2020.11, First Position: DVM student at Kansas State University
- Jake Willson, 2019.10-2020.05, First Position: Software Engineer, Cerner, Kansas City, MO

## ***Visiting Students/Scholars:***

- Dongping Zeng, 2016.10-2017.10, First Position: Associate Professor, South China Agricultural University, Guangzhou
- Paula Solar Oliver, 2017.02-2017.03, First Position: Executive Director at the Chilean Council of Foresight and Strategy
- Ning Xu, 2018.12-2019.12, First Position: Assistant Researcher, Chinese Academy of Fishery Sciences, Wuhan
- Yi-Jun Lin, 2019.07-2020.02, First Position: Assistant Professor, National Yang-Ming University, Taiwan
- Guanyu (Gabriel) Tao, 2021.07-2021.08 (summer intern), First Position: Senior Scientist, ADME & Discovery Toxicology Group, Merck, Boston, MA

# Expertise

## *Our Expertise:*

- Non-compartmental pharmacokinetic analysis
- Compartmental pharmacokinetic modeling
- Population pharmacokinetic (PopPK) analysis using nonlinear mixed effects (NLME) modeling
- Physiologically based pharmacokinetic (PBPK) modeling
- Population PBPK modeling using Monte Carlo simulations
- Bayesian population PBPK modeling using Markov chain Monte Carlo (MCMC) simulations
- Pharmacokinetic-pharmacodynamic (PK/PD) modeling
- Physiologically based pharmacokinetic-pharmacodynamic (PBPK/PD) modeling
- Probabilistic risk modeling and assessment
- Machine learning methods, including multiple linear regression, k-nearest neighbors, random forest and support vector machine
- Artificial neural network and deep learning

# Kan Shao, Ph.D.

- Education


- Dual PhD, Civil & Environmental Engineering and Engineering & Public Policy, Carnegie Mellon University (CMU), 2011
- MS, Machine Learning, CMU, 2011
- MS, Civil and Environmental Engineering, CMU, 2007
- BE, Environmental Engineering, University of Science and Technology Beijing, 2006

- Work Experience

- Associate Professor, Department of Environmental and Occupational Health, Indiana University, 2021 – present
- Assistant Professor, Department of Environmental and Occupational Health, Indiana University, 2014-2020
- Postdoctoral Fellow, US EPA / NCEA, 2011 – 2014



# Translational Nature of My Research



# Jean Lu Student Scholarship Award of AACT

- Established in 2009, giving its 1<sup>st</sup> recipient in 2010
- Initial generous gift from Dr. Frank C. Lu, a charter member of SOT, in memory of his wife, Jean Lu.



Jean Lu



Frank C. Lu

# Jean Lu Student Scholarship Award of AACT



**Karen Chiu, BS**  
**University of Illinois Urbana-Champaign**  
Mentor: Jodi A. Flaws, Ph.D

In recognition of  
outstanding  
academic  
achievement in  
the field of  
toxicology and  
who has  
provided  
leadership and  
service



**Hannah S. Xu, BS**  
**University of Georgia**  
Mentor: Tai L. Guo, Ph.D



# InnoStar Best Abstract Award of AACT

## *First Place*



**Zimu Wei, PhD**

***Michigan State University***

**Title:** Thrombin-catalyzed fibrin polymerization controls fibrin(ogen) solubility dynamics in early acetaminophen hepatotoxicity

**Mentor:** James Luyendyk, Professor

## *Second Place*



**Li Xia, BS**

***Perdue University***

**Title:** Modulation of Pulmonary Toxicity in Metabolic Syndrome (MetS) due to Variations in Nanoparticle-Biocorona Composition

**Mentor:** Jonathan Shannahan, PhD

## *Third Place*






**Chao Ji, PhD**

***Indiana University***

**Title:** Bayesian Benchmark Dose Estimation with BBMD: Inference from Genomic Data

**Mentor:** Kan Shao, PhD

# The 61<sup>st</sup> Annual Meeting (San Diego, March 27-31, 2022)



# During the 61<sup>st</sup> Annual Meeting (San Diego, March 27-31)



**Qian Lin, PhD**

**2021 Best Abstract Award**

**University of Louisville School of Medicine**

**Title:** A non-mitogenic FGF1 $\Delta$ HBS variant protects from nonalcoholic fatty liver disease via activating AMPK-mediated pathways

**Mentor:** Yi Tan, PhD

**Wei-Chun Chou, PhD**

**2021 Best Abstract Award**

**Kansas State University**

**Title:** Development of a web-based interface to facilitate nanomedicine design and safety assessment through the prediction of biodistribution of nanoparticles

**Mentor:** Zhoumeng Lin, PhD

**Shengjie Xu, BS**  
**2021 Jean Lu Student  
Scholarship Award**  
**Rutgers University**

**Mentor:** Joseph Antony  
Jude, Ph.D



# Appreciations for Outgoing Board Members




**Yongbin Zhang**  
(2019-2022)

President-Elect  
President  
Past President



**Quanshun Zhang**  
(2020-2022)

Councilor  
Treasurer



**Xiaoqing Guo**  
(2020-2022)

Councilor  
Secretary



**Hao Chen**  
(2020-2022)

Postdoc Representative



**Shengjie Xu**  
(2021-2022)

Student Representative

*Thank You!*

**A** MERICAN  
**A** SSOCIATION OF  
**C** HINESE IN  
**T** OXICOLOGY



北美中華毒理協會

# Looking Forward

**Xi Yang, PhD**

**AACT President (2022-2023)**


# 2022-2023 AACT Board Officers

---

<b>President:</b>	<b>Xi Yang</b>
<b>President-Elect:</b>	<b>Kan Shao</b>
<b>Secretary:</b>	<b>Dongying Li</b>
<b>Treasurer:</b>	<b>Xiefan Fang</b>
<b>Immediate Past President:</b>	<b>Nan Mei</b>
<b>Councilor:</b>	<b>Xiaoling Dai</b>
<b>Councilor:</b>	<b>Zhenquan Jia</b>
<b>Postdoc Rep:</b>	<b>Jie Luo</b>
<b>Student Rep:</b>	<b>Yunqi An</b>



# SOT 2019-2023 Strategic Plan





# Gold Sponsors' Presentations

---

**Dylan Yao, PhD**





**IT'S PERSONAL.**  
Driven to expedite your research journey.



The Heptagon






---

JOINN Laboratories and Biomere merged to form a premier, global nonclinical contract research organization (CRO). We have facilities on the east and west coasts, as well as multiple locations in China (JOINN).

Our global services portfolio, personal approach and our drive to expedite research timelines, makes us ideally suited to support our clients' needs.

# Visit **CRO EXPERTISE** at [Biomere.com](http://Biomere.com)



We specialize in solving challenges with unique solutions.





# THE CONCOURSE

Visit **THE CONCOURSE**,  
our private life science sharing community.

**Biomere.com**

Current life science webinars, blog, periodicals  
and procedural videos served by life science  
subject matter experts.

# Forum support is an abstract away



**Biomere**  
**FORUM  
SUPPORT**

**Accepting abstracts for 2023.**

Let us fund and support your upcoming scientific symposium.

Visit [biomere.com](https://biomere.com) FORUM SUPPORT for details, or e-mail

Deborah Curry at [dcurry@biomere.com](mailto:dcurry@biomere.com)



# Gold Sponsors' Presentations

---

**Tom Li**




**益诺思**  
INNOSTAR

# InnoStar Biotech

New Drug Safety Evaluation and Research





*Shanghai* **2010**

**Innostar Shanghai: 195K+ Sqft, 550+ Staff**

- Non-Clinical Safety Evaluation
- Pharmacokinetics
- GLP / non-GLP Toxicology
- Consulting Services



*Haimen* **2018**

**Innostar Nantong: 320K+ Sqft, 400+ Staff**

- Druggability Evaluation
- Efficacy Evaluation
- Comprehensive Ophthalmology Service Platform
- Non-Clinical Safety Evaluation
- Pharmacokinetics
- Isotopes and Imaging



*Shenzhen* **2020**

**Innostar Shenzhen: 100K+ Sqft, 50+ Staff**

- Non-Clinical Safety Evaluation
- Pharmacokinetics



*Huangshan* **2021**

**Innostar Huangshan: 150+ Acres**

- Primate Laboratory, Animal Breeding, and Research Lab






**Non-clinical  
Toxicology**



**DMPK**



**Bioanalysis**



**Biomarkers  
& Translational  
medicine**



**Regulatory  
Consulting  
Services**

## Achievements

**First** - Clinically approved oncolytic bacteria product

**First** - Oncolytic virus product concurrent approval for clinical use in China, the United States and Australia

Einuowei T3011

**First** - Clinically approved tetraspecific antibody

Sichuan Baili Pharmaceutical GNC-038

**First** - FDA-approved PD-1/CTLA-4 bispecific antibody Kangfang

Biotechnology AK104

**First** - Chinese medicine products approved by the Dutch government for marketing

Tongrentang Yufeng Ningxin Tablet

**First** - Biosimilar approved by EMA (trastuzumab) Shanghai Fuhong

Henlius Han Quyou

**First** - PD1 monoclonal antibody approved by NMPA Junshi Biology

**First** - 18F-APN-1607 Injection

Xinxu Biotechnology Company 18F-APN-1607 Injection

## Partners



## Successful NDA

Orbrutinib Tablets (BTK Inhibitor) Shanghai Tianjin Pharmaceutical Technology Co., Ltd. 2020.12.25

Porcine Fibrin Adhesive Shanghai Likangrui Biological Engineering Co., Ltd. 2021.4.1

SHR1459 Shanghai Hengrui Pharmaceutical Co., Ltd. 2020.12.24

JS001 Shanghai Junshi Biomedical Technology Co., Ltd. 2021.4

Bevacizumab injection (Boyunuo®) Shandong Boan Biotechnology Co., Ltd. 2021.5.7

Contezolid Tablets (MRX-I) Mengke Medical Technology (Shanghai) Co., Ltd. 2021.6.2

## Shanghai

28 SPF animal housing rooms

32 conventional animal housing rooms

## Haimen

62 SPF animal housing rooms

64 conventional animal housing rooms

## Shenzhen

14 SPF animal housing rooms

14 conventional animal housing rooms



## Environmental monitoring and maintenance

- Double corridor design prevent pollution for SPF area
- 24-hour Temperature, humidity and pressure monitoring
- Full fresh air system
- Quality test of drinking water quarterly
- Regularly test of ammonia concentration, the number of air exchange, air cleanliness, the falling bacteria and the cleanliness of the cage
- Backup power system
- Fully automatic cage washer and hydrogen peroxide disinfection transfer machine

## Animal Welfare

- Animal cages in accordance with Chinese national standards, US standards and EU standards
- Animal cages conforms to animal species-specific behavior
- Provide animal toys that match the animal species
- Feeding and supplement foods matches the characteristics of animal species
- Group-housing or pair-housing for social animals to meet social needs
- feeding and bedding substances is tested per batch

-  Rodent
-  Rabbit
-  Canine
-  Swine
-  Non-Human Primates

## Dosing Routes

- Injection
- Oral
- Sublingual/Buccal
- Inhalation/Pulmonary
- Transdermal
- Topical
- Rectal/Vaginal
- Etc

## Non-Human Primate Facility

14 facilities

200 rooms

86,000+ sq ft

Fully licensed animal breeding, production, and research facility

Quarantine and isolation rooms

Modern facility conforms to high standards



### **Innostar Shanghai**

Address: 199 guo shoujing road, China (Shanghai) pilot free trade zone

Post code: 201203    Tel: 021-60211999

### **Innostar Haimen**

Address: Haimen biomedical science and technology pioneer park (no. 100, dongting lake road)

### **Innostar Shenzhen**

Address: Building D, Shenzhen Institute of Drug Testing, Nanshan District, Shenzhen (No. 28, Gaoxin Middle Road, Nanshan District)

**US Contact**    [jtli@innostar.cn](mailto:jtli@innostar.cn)



# Thank You





# Gold Sponsors' Presentations

---

**Xuewei Wang, PhD**





**WestChina-Frontier Pharma Tech Co., Ltd**

# Company Profile

- TOP-Tier CRO in China Since 1999
- Nonclinical Evaluation of New Drug
- Founded Mainly by West China Hospital



# Over 20 Years Of Application Experience To NMPA & US FDA



> 80,000 m<sup>2</sup>




> 1000  
Employees



> 10% SDs

## Global Accreditation:

- AAALAC International
- NMPA GLP
- OECD GLP
- US FDA GLP Inspection
- US CAP
- CNAS



# Our Service

# Full-set Experimental System



Ophthalmic Drug



Inhalation Drug



Drug Dependence



Transdermal  
/Topical Drug



Cellular and Gene  
Therapy Product

**PD**

**DMPK**

- ADME in vitro and in vivo
- TK Study

**TOX**

- General toxicology
- Safety pharmacology
- Genetic toxicology
- Developmental and reproductive toxicology (Seg 1-4)
- Irritation, anaphylaxis , hemolysis
- Immunogenicity
- Carcinogenicity
- TCR
- Photosafety in vitro and in vivo

# Ophthalmic Drug Evaluation System

Advanced Equipment for Ophthalmology Imaging  
& Detection Facilitating Over 100 wAMD-Related Drugs Development




## Evaluation System:

- Efficacy in vivo
- PK/Biodistribution Study
- Toxicity Study



# Special Administration Route:

- Intravitreal Injection
- Subretinal Injection
- Suprachoroidal Injection
- Anterior Chamber Perfusion



# Inhalation Drug Evaluation System

---



## Advanced Oral-nasal Exposure System (GLP)

- Rodents, Dogs, NHPs

## Introduce 1<sup>st</sup> Rodent Exposure System in China

- Loading volume as low as 50 mg

## Dynamic Monitor of Oral-Nasal Exposure & Particle Size



# Cellular and Gene Therapy Product Evaluation System

## DMPK & Toxicity Evaluations

- Stem Cells
- Genetic Therapeutic Products
- CAR-T Products

## Analysis Platform:

- Nucleic Acid Amplification Detection (Q-PCR, ddPCR)
- Cell Sorting & Membrane Biomarker Detection via Flow Cytometry
- *In Vivo* Imaging via Micro-PET/CT or MRI
- IVIS Spectrum *In Vivo* Imaging System



*Looking Forward To  
Future Collaboration !*

**Email: [Service@glpcd.com](mailto:Service@glpcd.com)**

**[www.glpcd.com](http://www.glpcd.com)**

**WestChina-Frontier Pharma Tech Co., Ltd**

**A** MERICAN  
**A** SSOCIATION OF  
**C** HINESE IN  
**T** OXICOLOGY



北美中華毒理協會

# Open Discussion

# 2020 and 2021 AACT Award Plaques

Year	Type of Plaque	Awardee Name
2021	Award	Gabriel Tao
2021	Award	Qian Lin
2021	Award	Wei-Chun Chou
2021	Award	Ke-Jian Liu
2021	Award	Shengjie Xu
2021	Outgoing Officer	Tao Wang
2021	Outgoing Officer	Zunwei Chen
2021	Outgoing Officer	Suk (Cleo) Leung
2021	Outgoing Officer	Weimin Chen
2020	Award	Zunwei Chen
2020	Award	Yong Pu
2020	Award	Minhong Huang
2020	Award	Liang Chi
2020	Award	Lu Cai
2020	Outgoing Officer	X. Sherwin Yan
2020	Outgoing Officer	Li Zhan



**A** MERICAN  
**A** SSOCIATION OF  
**C** HINESE IN  
**T** OXICOLOGY



北美中華毒理協會

# Closing Remarks

# Please encourage your colleagues and students to join the AACT

		AACT
SOT member	regular member	<b>\$15</b>
	student/postdoc member	<b>free</b> for 1st SIG membership
Non-SOT member		<b>\$15</b>





## Important Dates and Deadlines

**Session Proposal Submissions**  
May 16, 2022

**Registration and Housing Open**  
August 1, 2022

**Award Nominations and Applications** **SOT**  
October 9, 2022

**Abstract Submissions**  
December 1, 2022

**AACT**



**THANK YOU EVERYONE**

**See you all next year in NASHVILLE**



**62nd Annual Meeting  
& ToxExpo • Nashville, TN  
March 19–23, 2023**